



Medi-Cal Rx

Medi-Cal Rx Monthly Bulletin

August 1, 2024

The monthly bulletin consists of alerts and notices posted to the [Bulletin & News](#) page on the Medi-Cal Rx Web Portal. Sign up for the [Medi-Cal Rx Subscription Service](#) to be notified when new information is posted.

1. [Changes to the Medi-Cal Rx Contract Drugs List](#)
2. [Changes to the Medi-Cal Rx Contract Drugs List – Over-the-Counter Drugs and Cough/Cold Preparations](#)
3. [Changes to the Medi-Cal Rx Family Planning, Access, Care, and Treatment Pharmacy Formulary](#)
4. [Updates to the Medi-Cal Rx Provider Manual](#)
5. [State of Emergency Override Activation: Submission Clarification Code 13](#)
6. [Mass Adjustment for Blood Factors for Impacted Claims Submitted January 1, 2022, through October 25, 2022](#)
7. [Mass Adjustment for Enteral Nutrition for Impacted Claims Submitted December 27, 2022, through March 13, 2023](#)

1. Changes to the Medi-Cal Rx Contract Drugs List

The below changes have been made to the [Medi-Cal Rx Contract Drugs List](#) posted to the Medi-Cal Rx Web Portal, effective August 1, 2024.

Drug Name	Description	Effective Date
Adapalene	Additional strength (0.3% gel) added to the <i>Medi-Cal Rx Contract Drugs List</i> (CDL).	August 1, 2024
Adapalene/Benzoyl Peroxide	Added to the CDL.	August 1, 2024
Asciminib	Additional strength (100 mg) added to the CDL.	August 1, 2024
Betamethasone Dipropionate	Additional formulation (lotion) added to the CDL.	August 1, 2024
Betamethasone/Propylene Glycol	Added to the CDL.	August 1, 2024
Betamethasone Valerate	Added to the CDL.	August 1, 2024
Clindamycin Phosphate/Benzoyl Peroxide	Additional strength (1.2% / 5%) and size (1% / 5%, 25-gram container) added to the CDL.	August 1, 2024
Duvelisib	Labeler code 71779 removed.	August 1, 2024
Fluoxetine HCL	Additional strengths (20 mg and 60 mg tablet) added to the CDL.	August 1, 2024
Nogapendekin Alfa Inbakicept-pmin	Added to the CDL with prior authorization required.	August 1, 2024
Pralsetinib	Labeler code 71332 added.	August 1, 2024
Tacrolimus	Additional formulation (ointment) added to the CDL.	August 1, 2024
Tarlatamab-dlle	Added to the CDL with labeler restriction.	August 1, 2024

2. Changes to the Medi-Cal Rx Contract Drugs List – Over-the-Counter Drugs and Cough/Cold Preparations

The below changes have been made to the [Medi-Cal Rx Contract Drugs List – Over-the-Counter Drugs and Cough/Cold Preparations](#) posted to the Medi-Cal Rx Web Portal, effective August 1, 2024.

Drug Name	Description	Effective Date
Acetaminophen	Additional strength (650 mg suppository) added to the <i>Medi-Cal Rx Contract Drugs List – Over-the-Counter Drugs and Cough/Cold Preparations</i> .	August 1, 2024

3. Changes to the Medi-Cal Rx Family Planning, Access, Care, and Treatment Pharmacy Formulary

The below changes have been made to the [Medi-Cal Rx Family Planning, Access, Care, and Treatment Pharmacy Formulary](#) posted to the Medi-Cal Rx Web Portal, effective August 1, 2024.

Drug Name	Description	Effective Date
Etonogestrel and Ethinyl Estradiol	Quantity Limit (QL) updated.	June 1, 2024
Levonorgestrel and Ethinyl Estradiol	QL updated.	June 1, 2024
Norelgestromin and Ethinyl Estradiol	QL updated.	June 1, 2024

4. Updates to the Medi-Cal Rx Provider Manual

The updates/additions below have been made to the [Medi-Cal Rx Provider Manual](#) version 21.0.

Updates

Section	Update Description	Effective Date
<i>Section 2.1.4.1 – Medi-Cal Provider Fraud, Waste, and Abuse</i>	<ul style="list-style-type: none"> Added an email contact to the “Medi-Cal Rx PI/SUI” row. Simplified contact information methods in the “Prime Therapeutics Special Investigations Unit (SIU)” row. Updated contact methods in the “Compliance” row. 	August 1, 2024

5. State of Emergency Override Activation: Submission Clarification Code 13

Background

The purpose of this alert is to notify pharmacy providers and prescribers that, pursuant to the Governor's recent [Proclamation of a State of Emergency](#) due to damage from the Thompson Fire in Butte County, Medi-Cal Rx is permitting emergency overrides on pharmacy claims for members residing in Butte County. These overrides will be accepted for 31 days, effective for dates of service (DOS) July 3, 2024, through August 4, 2024; however, the Department of Health Care Services (DHCS) may extend this duration if needed.

What Pharmacy Providers and Prescribers Need to Know

This emergency override will allow applicable claim submissions to bypass certain edits by utilizing the Submission Clarification Code (SCC) of 13. An SCC of 13 will indicate a Payer-Recognized Emergency/Disaster Assistance Request.

What Pharmacy Providers Need to Do

Pharmacy providers serving members residing within Butte County based on ZIP code, and who are requesting an emergency override due to the State of Emergency, should enter SCC 13 when submitting claims under the following circumstances:

- Reject Code 76 – Plan Limitations Exceeded
- Reject Code 83 – Duplicate Paid/Captured Claim
- Reject Code 88 – DUR Reject Error (such as, early refill, ingredient duplication, therapeutic duplication, etc.)
- Reject Code 606 – Brand Drug/Specific Labeler Code Required
- Reject Code 60 – Product/Service Not Covered For Patient Age
- Reject Code 61 – Product/Service Not Covered For Patient Gender
- Reject Code 75 – Prior Authorization Required

- » **SCC 13: By submitting SCC 13 on the claim, the pharmacy provider is attesting that the prescription and refill supply is dispensed in response to the natural disaster situation related to the recent *Proclamation of a State of Emergency* due to the Thompson Fire.**
- » **Reject Code 88: Pharmacy providers maintain their ability to override early refill at point of sale (POS) if medically necessary.**

Resources

- California Proclamation of State of Emergency:
 - [Thompson Fire](#)
- [NCPDP Payer Specification Sheet](#)
- [Medi-Cal Rx Billing Tips](#)
- [NCPDP Emergency Preparedness Guidance](#)
- Reject Code 88 Information:
 - [Now Active – Reinstatement of Reject Code 88](#)
 - [NCPDP Reject Code 88 DUR Reference Guide](#)
 - [Appendix A: Reject Code 88 DUR: Service Codes Scenarios](#)

6. Mass Adjustment for Blood Factors for Impacted Claims Submitted January 1, 2022, through October 25, 2022

Background

The purpose of this alert is to inform pharmacy providers that Medi-Cal Rx initiated a mass adjustment related to blood factor hemophilia products Alprolix®, Eloctate®, and NovoSeven® for claims submitted on or after January 1, 2022, through October 25, 2022.

What Pharmacy Providers Need to Know

Medi-Cal Rx identified a claims processing issue affecting a select number of claims submitted on or after January 1, 2022, through October 25, 2022, for the hemophilia drugs Alprolix, Eloctate, and NovoSeven with NDCs 00169720801, 71104080101, 71104080201, 71104080301, 71104080401, 71104080501, 71104080601, 71104080701, 71104080801, 71104080901, 71104081001, 71104091101, 71104092201, 71104093301, 71104094401, 71104096601, and 71104097701. Medi-Cal Rx updated the average sales price (ASP) for these NDCs on October 25, 2022, to correctly calculate reimbursement for blood factor claims per the Department of Health Care Services' (DHCS) policy.

Medi-Cal Rx has identified the impacted net paid claims and will be adjusting these claims on behalf of pharmacy providers which may result in an amount owed to you, an amount you owe DHCS, or no net change to the amount you were already reimbursed. Medi-Cal Rx will complete the claim adjustments in stages over the next several months.

Adjustments have been made for some of the impacted claims submitted January 1, 2022, through October 25, 2022, and appeared on the June 14, 2024, remittance advice (RA). Adjustments for the remaining claims submitted January 1, 2022, through October 25, 2022, will be processed by Medi-Cal Rx at a later date and a separate alert will be provided when that adjustment commences.

What Pharmacy Providers Need to Do

No action is required by pharmacy providers at this time.

Adjustments for the impacted claims submitted January 1, 2022, through October 25, 2022, are included on the June 14, 2024 RA. On the RA, impacted pharmacy providers will see a reversal of the original claim and a new claim processed (same member, Rx number, date of service, NDC, etc.) to reflect the adjustment.

For more information about this and other mass adjustment activities, refer to the [Mass Adjustments](#) page located on the [Medi-Cal Rx Provider Portal](#) or send a secured email to MediCalRxEducationOutreach@primetherapeutics.com and include, if appropriate, any claim-specific information with the correspondence.

7. Mass Adjustment for Enteral Nutrition for Impacted Claims Submitted December 27, 2022, through March 13, 2023

Background

The purpose of this alert is to inform pharmacy providers that Medi-Cal Rx initiated a mass adjustment specific to enteral nutrition contracted products Nutramigen® DHA-ARA and Peptamen Junior® 1.5 for claims submitted on or after December 27, 2022, through March 13, 2023.

What Pharmacy Providers Need to Know

Medi-Cal Rx identified a claims processing issue affecting a select number of claims submitted on or after December 27, 2022, through March 13, 2023, for enteral nutrition contracted products Nutramigen DHA-ARA and Peptamen Junior 1.5 with NDCs 00087049801 and 98716007363. For these enteral nutrition product claims, the Medi-Cal Rx reimbursement calculation used an incorrect price type which may have resulted in an incorrect pharmacy provider reimbursement. Medi-Cal Rx claim reimbursement calculation was updated on March 13, 2023, to utilize the correct Estimated Acquisition Cost (EAC) price type to calculate enteral nutrition product claims per the Department of Health Care Services' (DHCS) policy.

Medi-Cal Rx has identified the impacted net paid claims and will be adjusting these claims on behalf of pharmacy providers which may result in an amount you owe DHCS or no net change to the amount you were already reimbursed.

Adjustments have been made for some of the impacted claims submitted December 27, 2022, through March 13, 2023, and appeared on the June 14, 2024, remittance advice (RA). Adjustments for the remaining claims submitted December 27, 2022, through March 13, 2023, will be processed at a later date and a separate alert will be published when the next adjustment commences.

What Pharmacy Providers Need to Do

No action is required by pharmacy providers at this time.

Adjustments for the impacted claims submitted December 27, 2022, through March 13, 2023, appeared on the June 14, 2024 RA. On the RA, impacted pharmacy providers will see a reversal of the original claim and a new claim processed (same member, Rx number, date of service, NDC, etc.) to reflect the adjustment.

For more information about this and other mass adjustment activities, refer to the [Mass Adjustments](#) page located on the [Medi-Cal Rx Provider Portal](#) or send a secured email to MediCalRxEducationOutreach@primetherapeutics.com and include, if appropriate, any claim-specific information with the correspondence.

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@primetherapeutics.com.